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ROLE OF DOPAMINE D4 RECEPTOR IN THE GENOMIC AND
BEHAVIORAL EFFECTS OF PSYCHOSTIMULANTS:
RELEVANCE TO SCHIZOPHRENIA
Bina Garimella, M. S.
Western Michigan University, 2000
The role of dopamine D4 receptors in the induction and expression of
behavioral sensitization to amphetamine, cocaine and PCP was investigated in this
study. Behavioral changes and genomic responses accompanying sensitization were
examined using a highly selective D4 receptor antagonist, PNU-101387G. Induction
and expression of behavioral sensitization to cocaine was blocked by PNU-101387G.
However, the D4 antagonist did not modulate the induction and expression of
behavioral sensitization to PCP. Neuroadaptive genomic responses accompanying
acute and chronic effects of amphetamine and their modulation by PNU-101387G
was examined by looking at alterations in the expression of two immediate-early
genes: c-fos and NGFI-A. The D4 antagonist did not alter amphetamine-induced
. NGFI-A expression at 0.1 mg/kg or 1 mg/kg, but attenuated NGFI-A mRNA levels at
10 mg/kg. The 4-day pretreatment paradigm to examine the role of PNU-101387G in
the development of sensitization did not produce behavioral sensitization in response
to an amphetamine challenge on day 5. In addition, c-fos mRNA induction was not
attenuated significantly in these rats suggesting a dependence of some genomic
changes on withdrawal-induced neuroplasticity. Taken together, these data suggest a
prominent role for the D4 receptors in the development and expression of behavioral
sensitization to amphetamine and cocaine but not PCP.
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CHAPTER I
INTRODUCTION
Sensitization to psychostimulants in rodents 1s a phenomenon in which
repeated administration of psychotogens such as amphetamine, cocaine, and
phencyclidine (PCP) leads to a progressive augmentation in the locomotor stimulant
response (Post and Rose 1976). Behavioral augmentation due to a single injection
can last for a few hours whereas repeated injections administered for a few days or
weeks results in the effect of the drug persisting for months (Robinson and Becker
1986; Kalivas and Stewart 1991; Weiss et al. 1989).

Acute and chronic

administration of psychostimulants in experimental animals results in a characteristic
sequential change in behavior that is manifested over a period of time, and is a
function of dosage.

This sequential change in behavior is characterized by an

increase in motor activity in the beginning which eventually evolves into stereotyped
behaviors such as gnawing, chewing, sniffing etc. (Ellinwood & Balster 1974). In
particular, an acute injection of amphetamine in rats initially results in increased
hyperactivity involving an increase in forward locomotion, head movements,
sniffing, and rearing along with a concomitant decrease in normal behaviors like
grooming. This behavior is more frequently observed at lower doses and persists
over the duration of the drug's action.

With increasing doses, this initial

hyperactivity is followed by stereotyped behavior marked by a cessation in
locomotion and rearing and replaced by the animal assuming a crouched posture and
engaging in continuous or near continuous repetitive head movements, forelimb
movements, sniffing, licking and biting; with the intensity and duration increasing
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with increased dose of the drug. Behavioral sensitization is a common phenomenon
seen in many mammalian species including: cats, guinea pigs, mice, non-human
primates and humans

(Robinson and Becker 1986).

In humans, chronic

psychostimulant abuse can produce psychotic effects that are often not
distinguishable from paranoid schizophrenia (Pierce and Kalivas 1997). This has led
to the suggestion that psychostimulant-induced behavioral sensitization in animals
may model some aspects of schizophrenia. In fact this contention is supported by
evidence that mesolimbocortical dopamine system plays a central role in both
psychostimulant sensitization and schizophrenia as discussed below.
Lesion, pharmacological, biochemical and physiological studies suggest that
dopamine systems play a critical role in psychostimulant sensitization (Kalivas and
Stewart 1991; Koob 1996; Koob and Bloom 1988). The sensitization phenomenon is
thought to take place in two phases; induction and expression. Direct injection of
amphetamine or cocaine into the origin of the mesocortical and mesolimbic dopamine
pathways i.e. the ventral tegmental area (VTA) induce sensitization (Kalivas and
Weber 1988; Bjijou et al. 1996). On the other hand, expression of sensitization is
mediated by regions receiving these dopaminergic projections i.e. the nucleus
accumbens (Kalivas and Stewart 1991; Pierce and Kalivas 1997). It is apparent that
expression of sensitization is accompanied by greater release of dopamine in the
nucleus accumbens after the stimulant administration (Carboni et al. 1989; Kalivas
and Duffy 1990; Kalivas and Duffy 1993; Patrick et al. 1991; Robinson et al. 1988).
Additionally, lesions of the VTA block sensitization to amphetamine (Koob et al.
1981).

Finally, direct or peripheral injections of dopamine receptor antagonists

block the induction or expression of sensitization to cocaine and methamphetamine
(Ujike et. al 1989; Weiss et al. 1989).
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It is important to point out that in addition to dopaminergic systems, other
neurotransmitter systems may play a role in behavioral sensitization (Kalivas and
Duffy 1993; Wolf et al. 1993; White et al. 1995; Bedingfield et al. 1997). Notable
among them is the excitatory amino acid (BAA), glutamate, since antagonists of both
NMDA and non-NMDA ionotrophic glutamate receptors can block sensitization to
amphetamine (Kader et al. 1990; Wolf 1998). Glutamate transmission in the nucleus
accumbens is necessary also for the expression of cocaine induced behavioral
sensitization (Kalivas and Stewart 1991; White et al. 1995). Initiation of behavioral
sensitization involves stimulation of the NMDA receptors in the VTA resulting from
enhanced presynaptic release of excitatory amino acids (EAAs) following the
activation of D l dopamine receptors (Kalivas 1995a). Repeated administration of
amphetamine has been shown to result in an increased glutamate efflux from the
VTA and nucleus accumbens of rats indicating a role for glutamate in the
development and expression of behavioral sensitization to amphetamine (Xue et al.
1996). Similar results have been reported on cocaine-induced behavioral sensitization
where rats sensitized to cocaine showed an increase in glutamate release in the VTA
and nucleus accumbens of cocaine pretreated rats as compared to saline pretreated
rats (Kalivas and Duffy 1998; Reid and Berger 1996).

Recently, a role of

metabotropic glutamate receptors (mGluRs) has also been indicated based on
behavioral studies that implicate mGluR-specific glutaminergic transmission in Amp
or cocaine-induced motor behavior (Wang and McGinty 1998). A role of mGluRs in
behavioral sensitization to PCP has also been suggested based on studies
demonstrating that stimulation of group II mGluRs attenuated PCP-induced
locomotor activity and stereotypy (Moghaddam and Adams 1998). The NMDA
glutamate receptor is also involved in striatal induction of IEG expression following
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psychostimulant administration.

An attenuation of amphetamine and cocaine

induced IEG expression in the striatum following the blockade of NMDA receptors
has been reported (Torres and Rivier 1993; Wang et al 1994b; Konradi et al 1996).
The anatomical substrates involved in behavioral sensitization are primarily
the axon terminal fields in the striatum, nucleus accumbens, and prefrontal cortex, as
well as the dopamine cell bodies in the ventral tegmental area (Kalivas and Stewart
1991). The striatum is a principal nucleus of the basal ganglia, having complex
anatomical connections and containing high levels of neurotransmitters and
neuromodulators.

The caudatoputamen and nucleus accumbens regions of the

striatum receive excitatory input from most of the cerebral cortex (Gerfen et al.
1996). In addition, striatal neurons receive dopamine nerve terminals originating in
the substantia nigra and ventral tegmental area (Kalivas and Stewart 1991; Hurd and
Herkenham 1993). The striatum is therefore the site of integration of various neural
signals from regions of the brain like the prefrontal cortex that control emotions,
motivation and memory, as well as the ventral tegmental area that is considered to be
the site for the initiation of behavioral sensitization. Abnormalities in the basal
ganglia and their allied nuclei have been implicated in the addictive properties of
drugs of abuse as well as mental disorders like schizophrenia (Graybiel 1990). Drug
induced perturbations within the nervous system result in compensatory adaptations,
and the striatum has been identified as the primary site of these neuroadaptations
associated with behavioral sensitization (Koob and Bloom 1988). It is therefore
essential to study changes in the striatum in order to understand the mechanisms
underlying psychostimulant-induced neuronal plasticity.
Although chronic administration of amphetamine, cocaine and PCP results in
behavioral sensitization, pharmacological mechanisms underlying their effects are
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different.

Thus amphetamine targets dopamine (DA), serotonin (5-HT) and

norepinephrine (NE) transporters. It increases synaptic levels of DA, NE and 5-HT
by both transporter mediated release, and blockade of uptake (Robinson and Becker
1986). On the other hand, cocaine increases synaptic levels of DA, NE, and 5-HT by
blocking the respective transporter (Barker et al. 1994; Jayanthi et al. 1993; Kilty et
al. 1991).

Behavioral sensitization to amphetamine is likely due to increases in

synaptic dopamine levels since brain NE and 5-HT concentrations do not seem to be
affected by repeated intermittent amphetamine administration (Robinson and Becker
1986; Pierce and Kalivas 1997). Chronic administration of PCP also augments
locomotor activity but unlike amphetamine and cocaine that target monoamine
transporters, PCP acts as a non-competitive antagonist of the NMDA type of
glutamate receptor and also shows low affinity for the DA transporter (Javitt and
Jukin 1991; Jones et al. 1987). Hence distinct pharmacological specificity may be
observed for blockade of behavioral sensitization to amphetamine, cocaine or PCP.
As mentioned above, behavioral sensitization in rodents has been proposed
widely as an animal model for psychosis (Robinson and Becker 1986; Pierce and
Kalivas 1997).

This phenomenon occurs in two distinct phases termed as the

initiation phase, and the expression phase. These two phases are distinguishable as
they differ temporally and occur in anatomically distinct regions of the brain.
Initiation is thought to occur in the dopamine cell bodies of the VTA while the
expression involves dopamine terminal fields, especially the nucleus accumbens
(Kalivas 1995a; Pierce and Kalivas 1997). Even though cocaine and amphetamine
indirectly activate both the Dl and D2 family of dopamine receptors, it is widely
believed that the D1 dopamine receptors play a critical role in the development of
behavioral sensitization. These conclusions are based on studies demonstrating that
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microinjection of the Dl receptor antagonist, SCH 23390, into the VTA prior to
peripheral injections of amphetamine prevents the development of sensitization to
amphetamine (Stewart and Vezina 1989). Similarly, peripheral administration of
SCH 23390 with amphetamine prevents the development of sensitization (Bjijou et.
al. 1996). The role of D2 family (i.e. D2, D3, D4 receptor) in the induction of
sensitization is controversial. Thus, pretreatment with the D2 receptor antagonists,
pimozide and Ro 2 2- 2586 (Vezina and Stewart 1989) or sulpiride (Bjijou et al. 1996),
had no effect on the development of sensitization to amphetamine. In contrast, Ujike
et al. (1989), and Kurihara and Uchihashi (199 4) have demonstrated that the Dl
antagonist SCH 23390 and the D2 antagonist YM-09151- 2 both prevent the
development of behavioral sensitization to methamphetamine, indicating a role of D2
dopamine receptors in the development of psychostimulant sensitization. Ujike et al.
(1990) also suggest that methamphetamine- and cocaine-induced behavioral
sensitization occurs through a common neurobiological mechanism that involves
supersensitivity of postsynaptic D2 but not Dl dopamine receptors. A recent study
by Meng et al (1998) indicates that the discrepant findings on effects of D2 blockade
may be related to doses of the D2 antagonists. Thus at high doses, haloperidol and
clozapine induced cross-sensitization to amphetamine may have masked the blockade
of sensitization. On the other hand, lower doses of each agent blocked the induction
of behavioral sensitization to Amp as well as accompanying genomic changes. Thus
it is possible that in addition to the DI-like receptors, the D2-like receptor mediate
psychostimulant sensitization.

This is supported further by evidence in the Dl

knockout mouse where DI-deficient mice pretreated with amphetamine exhibited
behavioral sensitization in response to an amphetamine challenge (Crawford et al.
1997).
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Within the D2 family of dopamine receptors, D4 receptors are of particular
interest for several reasons. D4 receptors are primarily located in the cortex and
hippocampus regions of the brain, areas which are implicated in psychotic disorders
(Sokoloff and Schwartz 1995; Missale et al. 1998). Also notable is the preference of
the atypical antipsychotic clozapine for the D4 receptors (Van Toi et al. 1991).
Direct evidence of the D4 role in amphetamine sensitization was provided by recent
studies of selective D4 receptor antagonist, PNU-1013870 (Merchant et al. 1996).
PNU-1013870 blocks both initiation and expression of behavioral sensitization to
amphetamine as well as genomic and biochemical alterations associated with the
behavior (Feldpausch et. al. 1998). However, the molecular mechanisms underlying
the ability of the D4 receptor antagonist to block sensitization to amphetamine is as
yet unknown.
The overall goal of this study is to elucidate the molecular mechanisms
underlying the modulation of amphetamine effects by the D4 antagonist.
Specifically,

the

post-synaptic

genomic

changes

accompanymg

behavioral

sensitization and their modulation by D4 receptors are investigated using PNU1013870. Since these changes are triggered by the very first exposure to the drug,
the acute genomic effects in response to amphetamine and their modulation by the D4
antagonist are investigated. In addition, the genomic and behavioral effects during the
pretreatment or the initiation phase are also examined. Finally, the specificity of
blockade of behavioral sensitization to amphetamine by the D4 antagonist is
investigated by examining its effects on cocaine and PCP sensitization.

CHAPTER II
LITERATURE REVIEW
Prior work in psychostimulant sensitization that is relevant to the present
work may be classified into four major categories. The literature in each of these
areas is discussed below.

Following this discussion, the deficiencies in the

understanding of the mechanisms responsible for psychostimulant sensitization are
identified.
Acute Genomic Effects of Amphetamine
Since psychostimulant sensitization results from neuroadaptive responses,
short- and long-term genomic effects have been examined widely as markers of the
neuroplasticity produced by repeated stimulant exposure.

The acute or early

biochemical responses occur very rapidly in response to psychostimulants, and can
last from milliseconds to minutes (Hughes and Dragunow 1995). A majority of the
early responses involve alterations in expression of the so-called immediate-early
genes (IEG), several of which encode transcription factors. IEGs are induced in
response to a variety of stimuli (Hughes and Dragunow 1995; Sagar and Sharp 1993;
Sheng and Greenberg 1990), and alter the expression of target genes in a cell-specific
manner (Hughes and Dragunow 1995). Thus genomic responses produced by the
first exposure to a psychostimulant triggers a cascade of phenotypic alterations that
ultimately lead to an altered response to the next exposure to the stimulant. As
discussed earlier, the striatum is the site of integration of various neural signals from
regions of the brain like the prefrontal cortex that control emotions, motivation and
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memory, as well as the ventral tegmental area that is considered to be the site for the
initiation of behavioral sensitization. Drug-induced perturbations within the nervous
system result in compensatory adaptations, and the striatum has been identified as the
primary site of these neuroadaptations associated with behavioral sensitization (Koob
and Bloom 1988). It is therefore essential to study changes in the striatum in order to
understand the mechanisms underlying psychostimulant-induced neuronal plasticity.
In fact, a majority of the reports on psychostimulant-induced IEG and neuropeptide
expression have focused on the striatum as the primary substrate for the action of
drugs of abuse ( Simpson et al. 1995; Konradi et al. 1994; Hurd and Herkenham
1993; Cole et al. 1995; Ennulat et al. 1994; Wang and McGinty 1995a; Gerfen et al.
1995; Keefe and Gerfen 1995; Wang and Mcginty 1998; Wang and McGinty 1995b;
Cole et al. 1992; Graybiel et al. 1990; Moratalla et al. 1992; Nguyen et al. 1992). The
drugs of abuse most extensively studied have been amphetamine, methamphetamine
and cocaine. This review focuses mainly on the effects of amphetamine on two
immediate-early genes, c-fos and NGFI-A, and their modulation by dopamine
receptor antagonists.
The immediate-early genes, c-fos and NGFI-A, (also known as zif/268, egrl
and Krox-24) are induced in response to an acute administration of amphetamine in
the prefrontal cortex, nucleus accumbens and dorsal striatum (Graybiel et al. 1990;
Moratalla et al. 1992; Konradi et al. 1996; Wang and McGinty 1995; Cole et al. 1992;
Moratalla et al. 1992; Nguyen et al. 1992).
The pharmacological mechanisms fundamental to amphetamine-induced
immediate-early gene expression involve the dopaminergic system, and numerous
studies have investigated the role of the D l - and D2-like dopamine receptors in acute
effects of amphetamine.

Several pharmacological studies show that indirect
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activation of the Dl receptor by amphetamine produce c-fos and N GFI-A expression
in the neostriatum (Graybiel et al. 1990; Nguyen et al. 1992; Moratalla et al. 1992;
Young et al. 1991; Cole et al. 1992). Recent studies demonstrate also that the D2-like
receptors are involved in the acute effects of amphetamine. (Graybiel et al. 1990;
Ruskin and Marshall 1994). It is now well accepted that a combined activation of Dl
and D2 receptors is responsible for the acute genomic effects of amphetamine
(Ruskin and Marsha111 1 994; LaHoste et al. 1993; Robertson 1992).
Amphetamine Sensitization
The phenomenon of behavioral sensitization is the consequence of repeated,
intermittent amphetamine administration. Repeated, intermittent administration of
the same dose of amphetamine results in a progressive enhancement of the motor
stimulant effects of the drug. Furthermore, the effect of this enhanced sensitivity
persists long after the drug withdrawal (Robinson and Becker 1986). The VTA
dopamine receptors play a critical role in the initiation of sensitization.
Microinjection of amphetamine into the VTA can initiate behavioral sensitization to
subsequent amphetamine challenge (Kalivas and Weber 1988; Vezina 1993). Stewart
and Vezina (1989) and Bjijou et al. (1996) have demonstrated the importance of Dl
receptors in the initiation of sensitization to systemic amphetamine through studies
where the injection of a Dl antagonist, SCH 23390, into the VTA blocked the
initiation of behavioral sensitization produced by amphetamine administered
peripherally. These studies also showed that coadministration of the D2-like receptor
antagonists does not prevent the induction of behavioral sensitization to
amphetamine, suggesting a selective involvement of the Dl receptors in the initiation
of sensitization. The apparent selective involvement of the Dl receptors is in direct
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contrast to other studies demonstrating that peripheral injections of the D2-like
antagonist, YM-09151-2 blocked behavioral sensitization to methamphetamine
(Ujike et al. 1989). The contrasting effects of sulpiride and YM-09151-2 on the
induction of behavioral sensitization can perhaps be attributed to the nature of D2
receptor blockade by these antagonists. While both sulpiride and YM-09151-2 are
D2 receptor antagonists, sulpiride blocks the D2 and D3 receptors whereas YM09151-2 blocks the D4 receptor in addition to the D2 and D3 receptors, suggesting a
role of the D4 receptors in the initiation of behavioral sensitization. The involvement
of D2 receptors in behavioral sensitization has been implicated further in studies
showing a subsensitivity of the VTA D2 autoreceptors in amphetamine and cocaine
sensitized animals (Ackerman and White 1990; Henry et al. 1989; Wolf et al. 1993;
Bjijou et al. 1996). It has been suggested that the subsensitivity is a result of repeated
stimulation of the D2 receptor by amphetamine-induced dopamine and may indicate a
critical step in the initiation of behavioral sensitization.

C-fos is one of the most extensively studied IEG and repeated injections of
psychostimulants produced a diminished induction of c-fos expression (Bhat et al.
1992, Daunais and McGinty 1994; Hope et al. 1992; Moratalla et al. 1996; Persico et
al. 1993; Feldpausch et. al. 1998; Meng et. al. 1998; Cole et al. 1995 and Konradi et
al. 1996). However, Norman et al. (1993) have reported an augmentation of c-fos
expression in response to a second amphetamine injection given 3 days after the first
injection, and Curran et al. (1996) have demonstrated that sensitization to
amphetamine enhanced the expression of c-fos in the cerebral cortex. Jaber et al.
(1995) have reported that the phenotypic profiles of fos-positive neurons change in
response to acute vs chronic administrations of amphetamine. Acute amphetamine
resulted in 78% of the fos/fra positive neurons expressing PPT mRNA, which
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decreased to 56% following chronic administration. In contrast, coexpression of
fos/fra PPE mRNA was augmented from 33% to 52% in acute vs chronically treated
rats. The role of �FosB protein, belonging to the fos family of transcription factors
has become prominent in studies focusing on psychostimulant-induced IEG
expression. �FosB is derived from the fosB gene via alternative splicing and has a
truncated C terminus (Hiroi et al. 1997), and has been the focus of studies on the
chronic effects of drugs due to its prolonged induction kinetics and stability (Nestler
et al. 1999). An enhanced behavioral response to chronic cocaine in �FosB knockout
mice suggests that chronic cocaine-induced �osB serves as a compensatory
mechanism in the striatum to counter the action of cocaine (Hiroi et al. 1997).
Cocaine Sensitization
Like amphetamine, cocaine is a potent psychostimulant that augments
extracellular levels of dopamine by binding to the dopamine transporter and
preventing re-uptake (Kuhar et al. 1991).

The involvement of the mesolimbic

dopamine neurons has been implicated in cocaine sensitization based on reports that
repeated cocaine treatment increases the spontaneous activity of these neurons
(Henry et al. 1989a and b; Kalivas and Duffy 1993). Behavioral studies conducted by
Post and Rose (1976) and Kalivas and Stewart (1991) have demonstrated that
repeated daily administration of cocaine produces sensitization of locomotor activity.
This cocaine-induced increase in locomotor activity can be blocked by dopamine
antagonists directly microinjected into the nucleus accumbens or by destruction of
dopamine terminals in the nucleus accumbens.

Conversely, Kalivas and Duffy

(1993) showed that direct cocaine administration into the nucleus accumbens resulted
in locomotor activity. It is believed that both the Dl and D2 receptors are involved in
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the initiation and expression of behavioral sensitization to cocaine (Koob and Bloom
1988; Kalivas 1995b).
In studies to determine the effect of D1 and D2 receptor antagonists on the
development of sensitization to cocaine, Mattingly et al. (1994) have demonstrated an
attenuation in cocaine-induced behavioral sensitization in response to a challenge of
the D l receptor antagonist SCH 23390 or the D2 receptor antagonist sulpiride in
cocaine pretreated rats. However, coadministration of sulpiride or SCH 23390 with
cocaine during the pretreatment phase did not block the development of behavioral
sensitization to cocaine suggesting that behavioral sensitization to cocaine develops
through either the D l or D2 dopamine receptor. Henry et al. (1989a and b), Kamata
and Rebec (1983) and White and Wang (1984) have hypothesized that cocaine
sensitization is a result of subsensitivity of the dopamine D2 autoreceptors in the
substantia nigra and VTA.
PCP Sensitization
The mechanism of the action of PCP is via the blockade of the NMDA
receptor complex, and to a lesser extent, by the blockade of dopamine and serotonin
re-uptake (Nabeshima et al. 1995). Like amphetamine, PCP also induces psychosis
that resembles schizophrenia (Sams-Dodd 1998).

The positive symptoms of

schizophrenia, namely hallucinations and paranoia can be mimicked by
administration of either amphetamine or PCP. However, only PCP induces negative
symptoms of social withdrawal and blunted affect (Javitt and Jukin 1991). Chronic
administration of PCP results in behavioral sensitization (Xu and Domino 1994;
Johnson et al. 1998). Kitaichi et al. (1995) investigated PCP-induced behavioral
changes in animals and suggested that the development of sensitization to PCP may
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be caused by functional changes to dopaminergic neurotransmission. This is because
D2 receptor antagonists block the development of sensitization to PCP. Involvement
of dopamine receptors in PCP sensitization has also been demonstrated using
haloperidol, a D2 receptor selective antagonist.

In these studies, Kitaichi et. al.

(1995) and Nabeshima et al. (1995) have reported that coadministration of
haloperidol with PCP blocked the development of sensitization to PCP. Johnson et
al. (1998) have also reported that PCP-induced behavioral sensitization can be
significantly attenuated by pre-treatment with clozapine.

Although it has been

proposed that amphetamine, cocaine and PCP alter spontaneous behavior through
dopaminergic mechanisms, Greenberg and Segal, 1985 have demonstrated significant
differences in the neural mechanisms underlying sensitization to amphetamine and
PCP through cross-sensitization studies showing an asymmetric cross-sensitization
between amphetamine and PCP.

These studies have shown that chronic daily

injections of amphetamine resulted in animals being sensitized to the locomotor
stimulating effects of PCP. However, chronic daily injections of PCP did not result
in the development of behavioral sensitization in response to an amphetamine
challenge.
Need For Present Study
The above discussion on the literature pertaining to psychostimulant
sensitization shows that most of the studies involving the acute genomic effects and
behavioral effects of acute and chronic amphetamine, as well as sensitization to
cocaine and PCP have focused primarily on the D1- and D2-like receptors. Thus far,
the lack of highly selective antagonists against the individual members of the D1-like
(D1 and D5) and the D2-like (D2, D3, and D4) have limited the understanding of the
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role these receptors may ·play in behavioral sensitization. In particular, the preference
of the atypical antipsychotic clozapine for the D4 receptor indicates that this receptor
could be significant in explaining drug-induced psychosis as well as in diseases like
schizophrenia. In view of the recent availability of a highly selective D4 receptor
antagonist, PNU-1013870, and studies demonstrating its ability to block the
initiation and expression of sensitization to amphetamine (Merchant et. al. 1996,
Feldpausch et. al. 1998), it is essential to elucidate the molecular mechanisms
underlying the ability of the D4 antagonist to block sensitization. Therefore, the
present study focuses on using PNU-1013870 as a tool to understand the effects of
D4 receptor antagonism on the control of sensitization to psychostimulants. The
techniques used for investigating the genomic and behavioral effects of acute and
chronic amphetamine (as well as cocaine and PCP sensitization), and the results
obtained from these studies are discussed in the following chapters.

CHAPTER III
MATERIALS AND METHODS
Acute Genomic Effects of Amphetamine
The acute studies were conducted in order to investigate the effects of a single
injection of ct-amphetamine on immediate-early gene expression, and its modulation
by PNU-1013870. A dose-response profile of PNU-1013870 effects on acute Amp
induced genomic responses was generated using 0.1 mg/kg, 1 mg/kg, and 10 mg/kg
of PNU-1013870.
Animals
For all the studies, adult male, Sprague-Dawley rats (Harlan Laboratories,
Kalamazoo, Ml) weighing 175 to 200g at the beginning of the study, were maintained
in a controlled environment with a 12-hr light/dark cycle (lights on at 6:30 A. M.)
with free access to laboratory food and water.

Upon arrival, rats were housed

three/cage and after 5 days of acclimation they were randomly divided into their
respective pretreatment groups (n = 6/group), namely vehicle (V), amphetamine (A),
PNU-1013870 (U), and amphetamine+ PNU-1013870 (U+A).
Treatment Protocols
During the five day habituation period, the rats were handled daily to reduce
stress effects. ct-Amphetamine sulfate (2 mg/kg) was dissolved in saline and
administered s.c. PNU-1013870 (0.1, 1 or 10 mg/kg) was dissolved in 2% lactate in
16
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saline and administered IP. Each animal received 2 injections, one IP and one s.c.,
with appropriate vehicle controls to balance the number of injections across all
groups.

PNU-101387G was administered 10 minutes prior to the amphetamine

injection in the U+A group. The rats were sacrificed two hours post-treatment by
decapitation and brains were rapidly removed, frozen on liquid nitrogen, and stored at
°

-80 C until sectioning on a cryostat.
In Situ Hybridization Histochemistry
20 µm thick coronal sections through the neostriatum were cut on a cryostat at
°

°

-20 C and thaw-mounted onto gelatin-coated slides. The slides were stored at -80 C
until they were ready to be used. In situ hybridization was performed as per the
method described by Merchant et al. (1992). Slides were processed under RNAse
free conditions and all reagents were made in diethylpyrocarbonate (DEPC)-treated
water. Prior to processing, the slides were removed from the freezer and warmed to
room temperature for 12 minutes on aluminum foil. The slides were then fixed in 4%
w/v paraformaldehyde (4°C) for 5 minutes, rinsed in lX PBS (4°C) for 2 minutes,
acetylated with 0.25% v/v acetic anhydride in 0.1 M triethanolamine buffer (pH 8.0)
at R.T. for 10 minutes, dehydrated in a graded alcohol series (75%, 95% and 100%
v/v ethanol) at R.T. for 2 minutes each, delipidated in chloroform at R. T. for 5
minutes, and finally rinsed in 100% ethanol followed by rehydration in 95% ethanol
for 2 minutes each and air-dried.
A 45-base antisense deoxyoligonucleotide probe for NGFI-A complementary
to the coding region of rat NGFI-A gene (Genosys) was end-labeled using terminal
deoxynuleotidyl transferase (Boehringer Mannheim) and S-labeled dATP (Dupont
35

New England Nuclear). The average specific activity of the probe was approximately
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5.5 x 10 dpm/pmol. The labeled probe was then purified through NENsorb 20
6

°

column (Dupont NEN) and denatured at 70 C for 3 minutes before being added to the
hybridization mixture. The labeled probe were applied at a saturating concentration
of 2 pmol/rnl in the hybridization solution [10 mM Tris/lmM EDTA buffer, pH 8.0,
containing 50% v/v deionized formamide, 0.3 M NaCl, 10% w/v dextran sulfate, IX
Denhardt's solution, 200 mM dTT, and 0.5 mg/ml of yeast tRNA].
The sections were covered with silanized coverslips and incubated for 12-16
°
hours in a humid chamber. Hybridization was carried out at 37 C overnight. After

hybridization, the coverslips were removed by soaking in IX SSC, pH 7.0, (Gibco
BRL) for 30 minutes followed by a low stringency wash in IX SSC at room
temperature (RT) for 30 minutes. The hybridized sections were then subjected to a
°

series of three high stringency washes of 20 minutes each in IX SSC at 65 C,
followed by washes in IX SSC at RT and dehydration through a graded alcohol series
in which water was substituted by 0.6 M ammonium acetate (70%, 90% and 100%
ammonium acetate/ethanol). Following dehydration, slides were air-dried and film
autoradiograms were generated by apposing the brain sections to Kodak Biomax-MR
film (Kodak). The exposure times were determined based on the intensity of the
signal obtained on test films generated using one slide of each treatment group. The
aim was to generate the autoradiogram signal in a linear range of the 0. D. standards.
After an exposure time of 5 days, the films were developed in Kodak D-19 developer.
NGFI-A expression in the dorsomedial striatum was quantified by densitometric
analysis of film autoradiograms with a computer-assisted image analysis system.
Sections from all animals and treatment groups were atlas-matched (Paxinos and
Watson 1986). Data from all sections (left and right sides) from each animal were
pooled to obtain the average hybridization signal for each animal.
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Statistical Analysis
For each treatment group, the average hybridization signal was computed and
statistically analyzed using one-way analysis of variance (ANOVA).

When a

significant (p < 0.05) difference in variance was detected, Fisher's Least Square
Difference test was applied to identify groups differing from each other.
Amphetamine Senstization
Animals
As described for the study of acute genomic effects of amphetamine.
Animal treatment
The rats were divided into five treatment groups (n = 8/group) - VN, V/A,
A/A, U+A/A, and U/A, as shown in Table 1.

(The letter before the / denotes

pretreatment and that after the / shows the challenge treatment. Animals were treated
Table 1
Amphetamine Sensitization Treatment Groups
Chronic pretreatment
(dail )
vehicle I+ vehicle II
vehicle I+ vehicle II
vehicle II+ Amp
PNU-101387G + Amp
vehicle I+ PNU-101387G

Acute challenge

Group designation

vehicle
vehicle
vehicle
vehicle
vehicle

VN
V/A
A/A
U+A/A
U/A

I+ vehicle II
II+ Amp
II+ Amp
II+ Amp
II+ Amp

Note: Rats went through a 5-day treatment procedure, including chronic
pretreatment (daily from day 1 to day 4) and an acute challenge on day 5.
Amphetamine (2 mg/kg; as the sulfate salt) was dissolved in vehicle I (0.9
% normal saline) and administered subcutaneously. PNU-101387G was
dissolved in vehicle II (2% lactate in saline) and administered
intraperitoneally (10 mg/kg).
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with vehicle: saline (s.c.) plus 2% lactic acid (i.p.) at 1 ml/kg , vehicle plus d
amphetamine sulfate (2 mg/kg s.c.) dissolved in saline, PNU-101387G (10 mg/kg
i.p.) in 2% lactic acid plus saline, or a combination of PNU-101387G plus
amphetamine. For this 5 day treatment paradigm, animals were weighed every day
and then the respective drugs were administered either intraperitoneally or
subcutaneously between 8:00 and 9:00 A. M. at the indicated doses.

The

intraperitoneal injections were administered before the subcutaneous injections.
Pretreatment comprised of four daily injections of appropriate drugs or vehicle
followed by a challenge of the appropriate drug or vehicle on day 5. In addition, on
day 1 and day 5 of the treatment paradigm, the animals were behaviorally observed
and their locomotor activity was measured using the Digiscan Animal Activity
Monitoring System running DigiPro Windows software (Accuscan Instruments,
Columbus, · OH).

Eleven transparent Plexiglas activity monitoring chambers

measuring 40.5 x 40.5 cm comprised the monitoring apparatus. Each chamber was
equipped with 2 sets of 16 photocell arrays located at right angles to each other and
projecting horizontal infrared beams 2.5 cm apart and 3.75 cm above the cage floor
which could measure horizontal activity (primarily forward locomotion). Vertical
activity (primarily rearing) was measured by another set of 16 horizontal beams
placed 14 cm above the chamber floor. Horizontal activity counts were determined in
terms of each beam break in the lower array (regardless of the nature of activity)
whereas vertical activity was recorded whenever there was a beam break in the upper
array. Total distance (cm) was computed by the DigiPro Windows software using a
mathematical algorithm that took into account the distance between interrupted
beams, the length of the rat in the horizontal plane and the direction of ambulatory
activity (diagonal versus periphery). The rats were tested between 8:00 A.M. and
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4:00 P.M. with all eleven activity chambers being used simultaneously and all
treatment groups represented in each session. A Latin Square Design was used to
allocate rats from each treatment group in the test chambers. On test days 1 and 5,
each rat was placed in its respective chamber and allowed to habituate for 30 minutes
during which time its locomotor activity was recorded by the computer. The rats
were then removed briefly to receive the appropriate treatment and then put back in
the chamber.

The locomotor activity post-treatment was then measured for an

additional 60 minutes, and cumulative counts for horizontal activity, vertical activity
and total distance for the 60 minute test period were computed during the 60 minute
computerized recording of the locomotor activity, the rats were also manually
observed and behaviorally rated by investigators blinded to the treatment condition.
Starting at 5 minutes before the treatment and every 5 minutes for the next 60
minutes, the rats were observed for a period of 20 seconds and rated using a nine
point scale modified from Ellinwood and Balster (1974): (1) asleep, inactive; (2)
normal activities, grooming; (3) increased activity; (4) hyperactive running with jerky
movements; (5) slow patterened (repetitive exploration); (6) fast patterened
(repetitive exploration with hyperactivity); (7) stereotypy (repetitive sniffing/ rearing
in one location to the exclusion of other activities); (8) con�inuous gnawing, sniffing,
or licking; (9) dyskinesia, seizures. After the behavioral recordings, the rats were
sacrificed immediately by decapitation and the brains were rapidly frozen in liquid
nitrogen to be subsequently used for in situ hybridization histochemsitry.
In Situ Hybridization Histochemistry
The procedure followed for in situ hybridization was as described for the in
situ hybridization for acute genomic effects of amphetamine.

The radiolabeled
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antisense RNA probe for c-fos was synthesized in vitro usmg 35S-labeled UTP
(Amersham) in a reaction mixture that included lX transcription buffer, Bovine
Serum Albumin (50 µg/ml), 10 mM dTT, RNAse inhibitor (20U/1 00 µ1), 500 µM
each of ATP, CTP, GTP, 21 uM UTP and 3 uM S-UTP and the respective linearized
35

plasmid. The cDNA template corresponded to the full-length c-Jos gene and T7 RNA
polymerase (Boehringer Mannheim) was used for probe synthesis. The reaction
mixture was incubated at 37°C for 45 minutes, boosted with the respective RNA
polymerase and incubated further for 45 minutes. The template DNA was digested
°

with DNAse I at 37 C for 30 minutes. The labeled probe was purified using NENsorb
20 column. The average specific activity was 8 x 106 dpm/pmol for c-fos.
The labeled probe were applied at a saturating concentration of 2 pmol/ml in
the hybridization solution [10 mM Tris/lmM EDTA buffer, pH 8.0, containing 50%
v/v deionized formamide, 0.3 M NaCl, 10% w/v dextran sulfate, lX Denhardt's
solution, 10 mM dTT, and 0.5 mg/ml of yeast tRNA].
The sections were covered with silanized coverslips and incubated for 1 2-16
hours in a humid chamber at 56°C. After hybridization, the coverslips were removed
by soaking in lX SSC, pH 7.0, (Gibco BRL) for 30 minutes followed by a low
stringency wash in lX SSC at room temperature (RT) for 30 minutes. The c-fos
cRNA hybridized sections were treated with 20 µg/ml RNAse A (Sigma Chemical) in
°

a buffer containing 10 mM Tris HCl (pH 7.4), 0.5 M EDTA and 0.5 M NaCl at 37 C
°

for 45 minutes, followed by incubation in the buffer without RNAse A at 37 C for 30
minutes. Slides were washed in lX SSC at R. T. for 20 min before subjecting them
°

to a series of three high stringency washes of 20 minutes each in 0.lX SSC at 63 C.
Sections were then dehydrated in a graded alcohol series in which water was
substituted by 0.6 M ammonium acetate (70%, 90% and 100% ammonium
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acetate/ethanol).

Following dehydration,

slides

were air-dried and film

autoradiograms were generated by apposing the brain sections to Kodak Biomax-MR
film (Kodak). The exposure times were determined based on the intensity of the
signal obtained on test films generated using one slide of each treatment group. The
aim was to generate the autoradiogram signal in a linear range of the 0. D. standards.
After exposing the slides for 10 days, the films were developed in Kodak D-19
developer. c-fos expression in the prefrontal cortex was quantified by densitometric
analysis of film autoradiograms with a computer-assisted image analysis system.
Sections from all animals and treatment groups were atlas-matched (Paxinos and
Watson 1986). Data from all sections (left and right sides) from each animal were
pooled to obtain the average hybridization signal for each animal.
Statistical Analysis
For the computerized locomotor activity recordings, a repeated measure
analysis of variance was used to analyze the time-dependent effects, and when a
significant (p < 0.05) difference in variance was detected, Fisher's Least Square
Difference test was applied to identify groups differing from each other. For the
manual rating, a multifactorial analysis of variance (ANOV A) was performed. After
a significant difference (p < 0.05), a multiple comparisons Fisher's PLSD test was
applied to identify groups differing significantly from each other.
For the statistical analysis of in situ hybridization, the average hybridization
signal for each treatment group was computed and statistically analyzed using
ANOV A. When a significant (p < 0.05) difference in variance was detected, Fisher's
Least Square Difference test was applied to identify groups differing from each other.
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Cocaine and PCP Sensitization
A paradigm similar to that used for Amp sensitization was used to investigate
the effects of PNU-101387G on cocaine and PCP sensitization as detailed below.
Animals \
As described for the study of acute genomic effects of amphetamine.
Animal Treatment
For cocaine sensitization, rats were divided into the following pretreatment
groups (see Table 2): VehicleNehicle (VN; n = 5), Vehicle/Cocaine (V/C; n = 6),
Cocaine/Cocaine (C/C; n = 7), PNU-101387G+Cocaine/Cocaine (U+C/C; n = 7),
Cocaine/Cocaine+PNU101387G (C/C+U; n = 8), Cocaine/PNU-101387G (C/U; n =
7). Vehicle: saline (i.p.) and 2% lactic acid (i.p.) at 1 ml/kg, Cocaine (15 mg/kg, i.p.)
in saline, PNU-101387G (10 mg/kg i.p.) in 2% lactic acid, or a combination of PNU101387G plus cocaine.
For PCP sensitization, rats were divided into the following treatment groups:
Vehicle/Vehicle (V/V; n=7), Vehicle/PCP (V/PCP; n = 8), PCP/PCP (n = 8),
PCP+PNU-101387G/PCP

(PCP+U/PCP;

n

=

8),

PCP/PCP+PNU-101387G

(PCP/PCP+U; n = 8), PCP/Vehicle (PCPN; n = 8), and PCP/PNU-101387G (PCP/U;
n =8). Vehicle: saline (s.c.) or 2% lactic acid (i.p.) at 1 ml/kg, PCP (1 mg/kg, s.c.) in
saline, and PNU-101387G (10 mg/kg i.p.) in 2% lactic acid.

During the pre

treatment phase (Day 1-5), rats were weighed every day and the respective drugs
were administered either intraperitoneally or subcutaneously between 8:00 and 9:00
A. M, with the i.p. injection being given before the s.c. injection. The animals were
then returned to their home cages. Following a 10 day withdrawal period (Day 6-15),

rats were subsequently given a challenge injection on day 16 and their behavior was
observed, along with a computerized measurement of locomotor activity using the
Digiscan Animal Activity Monitoring System running DigiPro Windows software
(Accuscan Instruments, Columbus, OH) as described in the section on animal
treatment for the amphetamine sensitization studies.
Table 2
Cocaine and PCP Sensitization Treatment Groups

Cocaine
sensitization

Chronic pretreatment
(dail )
vehicle I+ vehicle II
vehicle I+ vehicle II
vehicle I+ cocaine
PNU-1013870+
Cocaine
vehicle I+ Cocaine
vehicle I+ Cocaine

PCP
sensitization

Acute challenge

Group designation

vehicle I+ vehicle II

VN

Cocaine
vehicle I+ cocaine
Vehicle I+ Cocaine

V/C
CIC
U+C/C

Cocaine+ PNU1013870
vehicle I+ PNU1013870

C/C+U
C/U

vehicle I+ vehicle II

vehicle I+ vehicle II

VN

vehicle I+ vehicle II
vehicle II+ PCP
PNU-1013870+
PCP
vehicle II+ PCP

vehicle II+ PCP
vehicle II+ PCP
vehicle II+ PCP

V/PCP
PCP/PCP
PCP+ U /PCP

PCP/PCP+ U
PNU-1013870+
PCP
vehicle I+ vehicle II PCP/V
vehicle II+ PCP
PCP/U
vehicle I+ PNUvehicle II+ PCP
1013870
Note: Rats went through a 16-day treatment procedure, including chronic
pretreatment (daily from day 1 to day 5), withdrawal (from day 6 to day
15) and acute challenge on day 16. Cocaine and PCP were dissolved in
vehicle I (0.9 % normal saline).
Cocaine was administered
intraperitoneally (15 mg/kg) and PCP was given subcutaneously (1 mg/kg).
PNU-1013870 was dissolved in vehicle II (2% lactate in saline) and
administered intraperitoneally (10 mg/kg).
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Statistical Analysis
As detailed in the section on amphetamine sensitization.
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CHAPTER IV
RESULTS
Acute Genomic Effects of Amphetamine
NGFI-A mRNA Expression in the Neostriatum
Study 1: Effects of 0.1 mg/kg PNU-101387O on Amp Effects
The effect of PNU-101387O on amphetamine-induced NGFI-A expression
was examined in the rostral (Bregma 1.60 mm to 1.00 mm) and caudal (Bregma 0.70
mm to 0.20 mm) sections of the striatum. In particular, NGFI-A expression levels in
the medial (DMSt) and lateral (DLSt) striatum and the cingulate cortex were
quantified by densitometric analysis of film autoradiograms. Figure 1 shows the
effects of PNU-101387O at 0.1 mg/kg on amphetamine-induced NGFI-A expression.
Acute administration of amphetamine augmented NGFI-A expression levels in the
DMSt in both rostral and caudal striatal sections.

Coadministration of the D4

antagonist (0.1 mg/kg) did not modulate amphetamine effects in the DMSt.
Amphetamine did not affect NGFI-A expression in the DLSt at either rostrocaudal
level and the levels of expression in the U+A group were similar to those seen with
amphetamine alone.

Expression of NGFI-A in the cingulate cortex was not

significantly augmented in the caudal cingulate cortex but showed a significant
increase in the rostral sections. PNU-1013987O did not have an effect on NGFI-A
expression induced by amphetamine. Thus at 0.1 mg/kg, PNU-101387O does not
modulate acute amp effects on NGFI-A in any region examined.
27
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The average hybridization signal from film autoradiograms were quantified as
described in "Materials and Methods". Each bar represents the group mean ±
SEM. Rats treated with amphetamine showed a significant induction of NGFI-A
expression in the rostral and caudal medial striatum. Concomitant treatment of
PNU-101387G (0.1 mg/kg) with amphetamine did not modulate amphetamine
induced NGFI-A expression in the medial and lateral striatum as well as the
cingulate cortex. * P < 0.05 versus vehicle (V).
Figure 1.

Quantification of NGFI-A mRNA Hybridization Signal in Striatum (0.1
mg/kg).

Study 2: Effects of 1 mg/kg PNU-101387G on Amp Effects
In the experiment examining the effects of PNU-101387G at 1 mg/kg,
amphetamine induced NGFI-A mRNA expression in the DMSt in both rostral and
caudal sections (Figure 2).

As before, amphetamine did not increase NGFI-A

expression in the DLSt of the rostral sections. However, unlike the first study an
increase in the caudal DLSt as well as rostral and caudal cingulate cortex was

evident. Concomitant treatment of PNU-101387G along with amphetamine (U+A)
did not significantly alter amphetamine-induced NGFI-A expression in any region
demonstrating that PNU-101387G at 1 mg/kg does not modulate acute amphetamine
induced NGFI-A effects.
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The average hybridization signal from film autoradiograms were quantified as
described in "Materials and Methods". Each bar represents the group mean ±
SEM. Rats treated with amphetamine showed a significant induction of NGFI-A
expression in all three regions of the rostral and caudal striatum. Concomitant
treatment of PNU-101387G (1 mg/kg) with amphetamine did not modulate
amphetamine-induced NGFI-A expression. * P < 0.05 versus vehicle (V).
Figure 2.

Quantification of NGFI-A mRNA Hybridization Signal in Striatum (1
mg/kg).

Study 3: Effects of 10 mg/kg PNU-101387G on Amp Effects
In this study, amphetamine caused a significant augmentation m NGFI-A
mRNA expression in the DMSt, DLSt and cingulate cortex in both the rostral and
caudal sections, as shown in Figure 3. Coadministration of PNU-101387G along
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with amphetamine did not significantly attenuate amphetamine-induced NGFI-A
expression in the caudal DMSt and DLSt at both rostrocaudal levels. Amphetamine
induced NGI-A mRNA expression in the cingulate cortex was not modified by PNU101387G.
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The average hybridization signal from film autoradiograms were quantified as
described in "Materials and Methods". Each bar represents the group mean ±
SEM. Amphetamine treated rats (A) showed a significant induction of NGFI-A
mRNA expression in the rostral and caudal striatum. Coadministration of PNU101387G (10 mg/kg) caused a significant attenuation of amphetamine-induced
NGFI-A expression in the rostral lateral striatum and also in the caudal medial and
lateral striatal regions. * P < 0.05 versus vehicle (V); # P < 0.05 versus
amphetamine (A).
Figure 3.

Quantification of NGFI-A mRNA Hybridization Signal in Striatum (10
mg/kg).
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Effects of PNU-101387G on Amphetamine Sensitization
Locomotor Activity and Behavior
On day 1 of the 5 day pretreatment phase, rats treated with vehicle or PNU101387G (10 mg/kg) by itself (groups VN, V/A, U/A) showed similar levels of
activity (Figure 4). Administration of amphetamine (NA group) caused a significant
increase in horizontal and vertical activities as well as the total distance traveled.
Concomitant treatment of PNU-101387G along with amphetamine (A+U/U group)
resulted in a similar level of activity as seen in the NA group, i.e. PNU-101387G did
not affect behavioral response to the first dose of amphetamine. A factorial analysis
of variance of the cumulative counts taken over the one hour locomotor activity
measurement period on day 5 shows that an acute amphetamine challenge in vehicle
pretreated animals (V/A) caused a significant increase in locomotor activity. This
augmentation was observed in all three categories i.e. horizontal activity, vertical
activity and total distance.

Surprisingly, animals pretreated with amphetamine

showed diminished locomotor activity upon amphetamine challenge (NA) in
horizontal activity, vertical activity as well as total distance traveled, compared to
vehicle pretreated animals challenged with amphetamine (V/A). Coadministration of
PNU-101387G along with amphetamine during the pretreatment phase seemed to
restore the horizontal activity and total distance traveled to levels seen in the V/A
group (i.e. U+NA=V/A).

However, the vertical activity appeared to be further

attenuated. An amphetamine challenge in rats pretreated with the D4 antagonist
alone affected the horizontal and vertical activities in a similar manner as the V/A
group but decreased the total distance counts.
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The cumulative (HA), vertical (VA) and total distance (TD) counts from day 1 (D1) and
day 5 (D5) of the behavioral studies are shown. Each bar represents the group mean ±
SEM. On day 1, rats treated with amphetamine showed a significant increase in the
horizontal and vertical activities as well as the total distance traveled compared to animals
treated with vehicle or PNU-101387G. On day 5, amphetamine augmented locomotor
activity in rats pretreated with vehicle (V/A). However, there was a significant
attenuation of locomotor activity in amphetamine pretreated rats (A/A). Concomitant
treatment of PNU-101387G restored levels of horizontal activity and total distance to that
seen in the V/A group. * P < 0.05 versus VN; # P < 0.05 versus V/A.
Figure 4.

Cumulative Locomotor Activity in Amphetamine Sensitization.
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A factorial analysis of variance followed by the Fisher's PLSD test for the
manual counts on day 1 showed results similar to those seen in the computerized
measurements (Figure 5). On day 5, an acute challenge of amphetamine in vehicle
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Cumulative observation counts taken on day 1 (D1) and day 5 (D5) are shown.
Each bar · represents the group mean ± SEM. On day 1, rats treated with
amphetamine or a combination of PNU-101387G and amphetamine showed a
significant increase in stereotyped behavior compared to rats treated with vehicle
or PNU-101387G alone. On day 5, amphetamine significantly augmented
stereotyped behavior in the vehicle and amphetamine pretreated rats (V/A and
NA). Note that pretreatment with amphetamine in the NA group did not
significantly alter activity compared to the VN group. In the U+NA group, the
amphetamine challenge attenuated the behavioral counts compared to the V/A and
the NA group. * P < 0.05 versus V/A; # P < 0.05 versus NA.
Figure 5.

Cumulative Manual Observation Counts for Amphetamine Sensitization.

pretreated rats caused a robust increase in behavior.

Animals pretreated with

amphetamine did not display any further augmentation in behavior in response to the
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amphetamine

challenge.

Coadministration

of PNU-1013870

along with

amphetamine during pretreatment (U+NA group) appeared to decrease the activity
compared to the NA group.
c-fos mRNA Expression in the Prefrontal Cortex
c-fos mRNA expression was examined in the IL/PL and cingulate cortical
regions (Bregma 4.20 mm to 3.20 mm).

Animals pretreated with vehicle

demonstrated a robust augmentation in c-fos mRNA expression upon an acute
challenge with amphetamine (Figure 6). However, no significant attenuation of this
response was observed in rats pretreated with amphetamine and subsequently
challenged with amphetamine (NA).

C-fos mRNA expression levels in animals

pretreated with PNU-1013870 by itself and subsequently challenged with
amphetamine (U/A) were similar to the NA group but were attenuated compared to
the V/A group in the prelimbic and cingulate cortex regions.

Additionally,

cotreatment of PNU-1013870 along with amphetamine (U+NA) did not restore c-fos
induction to the level seen in V/A.
Effects of PNU-1013870 on Cocaine and PCP Sensitization
Cocaine Sensitization
The modulation of cocaine-induced behavioral sensitization by the D4
antagonist was examined through computerized measurements of locomotor activity,
as well as manual ratings. As seen in Figure 7, a repeated measure analysis of
variance followed by the Fisher's PLSD test demonstrates a significant effect of
cocaine treatment on locomotor activity as well as a modulation of this activity by
PNU-1013870 over time. Rats pretreated with vehicle showed a significant increase

in motor activity in response to acute challenge of cocaine (V/C). This increase was
seen in the horizontal activity, vertical activity and total distance. Cocaine pretreated
rats showed a robust sensitization upon cocaine challenge (C/C) with significant
increases in horizontal and vertical activities as well as total distance.
Coadministration of the D4 antagonist along with cocaine during the pretreatment
phase resulted in a significant attenuation in locomotor activity upon a cocaine

0.20
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Regions

c-fos mRNA levels were quantified from film autoradiograms as detailed in
"Materials and Methods". Each bar represents the group mean± SEM. An acute
amphetamine challenge augmented c-fos mRNA levels in the infralimbic,
prelimbic and cingulate cortex of vehicle pretreated rats (V/A). There was no
further augmentation observed in the amphetamine pretreated rats (AlA) and there
was no significant difference between the A/A and A+U/A group. * P < 0.05 vs.
V/V.
Figure 6.

Quantification of c�fos mRNA Expression in the Prefrontal Cortex.
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Rats were pretreated with vehicle, cocaine or a combination of PNU-1013870 plus cocaine as
described in "Materials and Methods". The horizontal, vertical and total distance counts were
computed following the appropriate chaJienge injection. Each point represents the cumulative
activity counts for a 10 minute period. Groups differing from each other were identified by
statistical analysis using repeated measure analysis of variance followed by Fisher's PLSD.
Behavioral sensitization was observed primarily in the horizontal activity counts and total distance
traveled. Coadministration of PNU-1013870 with cocaine during pretreatment as well as on the
chaJlenge day blocked behavioral sensitization. Note that cotreatment also attenuated vertical
activity counts in the C+UIC and CIC+U groups compared to the CIC group. * P < 0.05 versus
VIC; # P < 0.05 versus CIC.

Figure 7.

Time Course of Locomotor Activity in Cocaine Sensitization.
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challenge (C+U/C). This blockade of behavioral sensitization was observed in the
horizontal and vertical activities and the total distance. A challenge of cocaine and
PNU-101387G (C/C+U) in cocaine pretreated animals also produced a significant
decrease in locomotor activity than seen in the CIC group. Factorial analysis of
variance with cumulative counts over the one hour period showed that a cocaine
challenge in cocaine pretreated rats (C/C) produced an increase in locomotor activity
primarily in the horizontal activity counts and total distance traveled but not in
vertical activity. Coadministration of PNU-101387G during the pretreatment phase
(C+U/C) and a challenge in the cocaine pretreated animals (C/C+U) significantly
attenuated cocaine-induced behavioral sensitization.
The manual observations showed a similar pattern of a blockade of cocaine
induced behavioral sensitization.

Figure 8 illustrates a robust sensitization upon

cocaine challenge in cocaine pretreated rats (C/C).

Coadministration of PNU-

101387G along with cocaine during the five day pretreatment phase (C+U/C) caused
a significant attenuation of sensitized behavior. Additionally, a challenge of the D4
antagonist along with cocaine in cocaine pretreated rats (C/C+U) also resulted in a
significant decrease in sensitized behavior.
PCP Sensitization
Figure 9 shows that an acute PCP challenge in vehicle pretreated rats (V/PCP)
did not produce a significant increase in locomotor activity. The repeated measure
analysis of variance followed by the Fisher's PLSD test shows that this lack of an
effect was observed in all three measures; namely horizontal activity, vertical activity
and total distance. However, a PCP challenge in PCP pretreated rats (PCP/PCP)
produced a significant increase in horizontal and vertical activities as well as total
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Rats were pretreated with vehicle, cocaine or a combination of PNU-101387G
plus cocaine and rated for 60 mins post-treatment as described in "Materials and
Methods". Each bar represents the group mean ± SEM. Rats pretreated with
cocaine showed a significant augmentation in sensitized behavior compared to
vehicle pretreated rats. Behavioral s.enstization was blocked by coadministration
of PNU-101387G and cocaine during pretreatment or on the challenge day. * P <
0.05 versus V/C; # P < 0.05 versus CIC.

Figure 8.

Manual Observation Counts for Cocaine Sensitization.

distance traveled compared to rats pretreated with vehicle (PCP/PCP versus V/PCP).
The behavioral sensitization observed was more evident in the frrst 30 minutes of
activity and seemed to decrease in the last 30 minutes. In rats coadministered PNU101387G along with PCP during the pretreatment phase (PCP+U/PCP), or challenged
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with the combination (PCP/PCP+U), there was no significant difference in locomotor
activity when compared to rats that displayed behavioral sensitization to PCP
(PCP/PCP). This was seen in horizontal activity and vertical activity counts as well
as the total distance counts. However, a slightly different pattern was observed upon
manually rating of the behavior of rats upon treatment with PCP. In contrast to the
results of the automated activity measures, manual rating of the behavior
demonstrated that an acute PCP challenge in vehicle pretreated rats induced
locomotor activation (Figure 10). This effect was significantly augmented in rats
pretreated with PCP (PCP/PCP=PCP/PCP). Coadminstration of PNU-101387G with
PCP during pretreatment did not block behavioral sensitization to PCP
(PCP+U/PCP). Although a challenge of PNU-101387G along with PCP in PCP
pretreated rats appeared to attenuate behavioral sensitization, this effect was
significant at trend level (p < 0.06). Challenges with vehicle or PNU-101387G in
PCP pretreated rats produced similar levels of activity as seen in vehicle pretreated
rats that were subsequently challenged with vehicle.

40

UI

8000 ,------

5

6000

�
·s:

4000

C

ca

]j
C

2000

-�

0

0
0

-------- ---,
--vN
-<>- VIP
-- PIP
-<>-- P+UIP
---•--- PIP+U

-o- PN

-•- P/U

::c
0
10
20
30
40
50
60
70
180 �----- -------- �
!!
C

160

�
·s:

100

ca

60
40
20
0

140

0 120
u

B
t:
Cl)

--vN
____,,_ VIP
-- PIP
-<>-- P+UIP
----•---- PIP+U

80

-o- PN

-- P/U

0
10
20
30
40
50
60
70
5000 �------- -- - -�
!!
C

4000

C

2000

-----<>- --<>-----�---

0
u 3000
Cl)
u
UI

i

--0-

1000

VN
VIP
PIP
P+UIP
PIP+U

PN

--- P/U

0
0

10

20

30

40

50

60

70

Time period

Rats were pretreated with vehicle, PCP or a combination of PNU-101387G plus PCP as described
in "Materials and Methods". The horizontal, vertical and total distance counts were computed
following the appropriate challenge injection. Each point represents the cumulative activity counts
for a 10 minute period. Groups differing from each other were identified by statistical analysis
using repeated measure analysis of variance followed by Fisher's PLSD. An acute challenge of
PCP in vehicle pretreated rats (VIP) did not significantly augment locomotor activity compared to
rats pretreated with vehicle (VN). Rats pretreated with PCP (PIP) showed a significant
augmentation of horizontal and vertical activities and total distance traveled compared to the VIP
group. Coadministration of PNU-101387G and PCP during pretreatment or on the challenge day,
did not modulate the effects of PCP. * P < 0.05 versus VN; # P < 0.05 versus VIP.

Figure 9.

Time Course of Locomotor Activity in PCP Sensitization.
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Rats were pretreated with vehicle, PCP or a combination of PNU-1013870 plus PCP and rated for
60 rnins post-treatment as described in "Materials and Methods". Each bar represents the group
mean ± SEM. Rats pretreated with PCP showed a significant augmentation in sensitized behavior
compared to vehicle pretreated rats. Concomitant treatment of PNU-1013870 along with PCP on
the challenge day blocked behavioral sensitization in PCP pretreated rats. Concomitant treatment
during pretreatment also appeared to block sensitized behavior although this blockade approached
trend level significance (P < 0.06). * P < 0.05 versus VIP; # P < 0.05 versus PIP.

Figure 10.

Manual Observation Counts for PCP Sensitization.

CHAPTER V
DISCUSSION
Acute Genomic Effects of Amphetamine
NGFI-A is a transcription factor that belongs to the zinc finger family of
immediate-early genes, and like c-fos, is robustly induced upon neural stimulation.
Psychostimulants like amphetamine and cocaine have been shown to induce NGFI-A
mRNA expression in the caudatoptamen and ventral striatum in rats (Moratalla et al,
1992, Nguyen et al 1992; Cole et al, 1992).

In the present study, we have

investigated a role for the D4 dopamine receptors in modulating amphetamine
induced NGFI-A expression.

Consistent with previous studies, amphetamine

augmented the expression of NGFI-A in the striatum. However, there appears to be
some variation in the regional expression of Amp-induced NGFI-A levels in the three
studies.

Concomitant administration of the D4 antagonist at 10 mg/kg plus

amphetamine attenuated NGFI-A mRNA expression. These data are consistent with
Feldpausch et al. (1998) observation that at 10 mg/kg, PNU-101387G blocks the
induction of sensitization to amphetamine. Since 0.1 mg/kg of PNU-101387G also
blocks induction and expression of amphetamine sensitization, other factors may also
be a contributing factor.

Cole et al.(1992) and Moratalla et al. (1992) have

demonstrated that striatal D1 dopamine receptors play a critical role in amphetamine
induced NGFI-A expression .. Both these studies showed that pretreatment with the
DI receptor antagonist, SCH 23390, attenuated amphetamine-induced NGFI-A
expression. Taken together, these results suggest that NGF-A expression may be
42

43
primarily mediated through the D1 dopamine receptors.
In addition to the neostriatum, the medial prefrontal cortex has also been
targeted as an important site of neuroadaptive changes involved in psychostimulant
sensitization (Meng et. al 1998, Feldpausch et. al. 1998, Karler 1997). The present
studies demonstrate that acute amphetamine (V/A) significantly increased c-fos
mRNA expression in the prefrontal cotex.

However, there was no significant

attenuation of this response in the amphetamine pretreated group (AfA).

These

results are in contrast to previous studies demonstrating a reduction in c-fos mRNA
levels in amphetamine sensitized rats (Meng et. al. 1998). In contrast to studies
demonstrating the ability of D2-like receptor antagonists, haloperidol and clozapine,
to reverse this attenuation, coadministration of the D4 antagonist during the four day
pretreatment did not significantly block the decrease in the capacity of amphetamine
to induce c-fos mRNA ( U+AfA = NA group). One possible explanation is that
previous studies of haloperidol and clozapine examined Amp-induced c-fos
expression after a seven day withdrawal period. In the present study protocol, no
withdrawal was employed.

It should also be noted that the 5 day pretreatment

regimen did not result in behavioral sensitization which is in direct contrast to other
studies showing that repeated, intermittent injections lead to an augmentation in the
behavioral response (Feldpausch et. al. 1998, Meng et. al. 1998 as well as Pierce and
Kalivas 1997). Thus, some of the genomic responses accompanying sensitization
may be dependent on withdrawal-induced neuroplasticity.
Behavioral Effects of Amphetamine
A withdrawal period has been suggested as being a critical factor in the
development of sensitization (Pierce and Kalivas 1997).

However, Wang and
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McGinty (1995) have reported behavioral sensitization using a five day treatment
paradigm involving repeated administration of the same dose of amphetamine
without a withdrawal period. It should be noted that the dose used was higher (5
mg/kg versus 2 mg/kg) as also the route of injection (i.p. versus s.c). Behavioral
sensitization following repeated administration of very low doses (<1.0 mg/kg) and
very high doses (10 mg/kg) has also been reported (Robinson and Becker, 1986).
Therefore, the absence of behavioral sensitization in this study in any of the activities
i.e horizontal activity, vertical activity and total distance is puzzling.

Visual

observations of the rats to detect a qualitative shift in behavior also led to the same
results with no sensitization being observed in the amphetamine pretreated rats,
indicating that the lack of an increase in the horizontal, vertical and total distance
traveled counts was not due to shift from locomotor activity to stereotypy.
Behavioral Effects of Cocaine
The significant increase in locomotor activity in response to a cocame
challenge observed in the cocaine pretreated rats indicates a robust sensitization. In
order to eliminate the possibility of a context-dependent sensitization, administration
of cocaine during the pretreatment phase was carried out exclusively in the home
cages. The rats were introduced to the locomotor activity boxes for the frrst time on
the day of the challenge injection prior to testing. Additionally, the effects of stress
on behavioral measurements was reduced by giving all the groups an equal number of
injections during the pretreatment and testing phase and also allowing the animals to
habituate to the locomotor activity boxes for 30 minutes prior to the challenge.
Therefore, the behavioral sensitization to cocaine and the blockade by the D4
antagonist can be considered to be a direct consequence of the action of these drugs.
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Measurement of the locomotor activity involved the observation of the
horizontal activity (locomotion), vertical activity (rearing) and an indirect
measurement of focused stereotypy by measuring the total distance traveled. In this
study, behavioral sensitization was manifested mainly by an increase in locomotion,
since the sensitization was primarily observed in the horizontal activity counts and
the total distance traveled and not in rearing or stereotypy. Coadministration of
PNU-101387G with cocaine during pretreatment phase blocked the induction and
expression of behavioral sensitization to cocaine in the horizontal activity, vertical
activity and total distance counts. This was demonstrated by an attenuation in
locomotor activity in rats that were pretreated with a combination of cocaine and the
D4 antagonist and then challenged with cocaine (C+U/C) as well as in cocaine
pretreated rats that received a challenge of the D4 antagonist and cocaine (C/C+U).
Examination of the manual rating scores showed that cocaine-sensitized rats (C/C)
primarily demonstrated stereotypy (repetitive sniffing/rearing in one location to
exclusion of other activities. The concomitant administration of PNU-101387G with
cocaine during the pretreatment phase (C+U/C) or the challenge in cocaine pretreated
rats (C/C+U) resulted in the rats primarily exhibiting a slow patterned (repetitive
exploration) activity. Administration of the D4 antagonist therefore attenuated the
behavior from a more intense stereotypic activity (score of 7) to a less intense
locomotor activity (score of 5).

The manual observations therefore confirm the

results of the computerized measurements and therefore show a true blockade of the
induction and expression of behavioral sensitization to cocaine.
These results are significant since the current literature on the effects of
dopamine receptor antagonists on behavioral sensitization to cocaine are often
conflicting. For example, studies by McGreary and Marsden (1993) as well as Weiss

et al (1989) have demonstrated that dopamine receptor antagonists can inhibit
behavioral sensitization to cocaine. Conversely, other studies have demonstrated that
both D1 and D2 receptor antagonists were unable to block the induction of behavioral
sensitization to cocaine (White et. al. 1998, Mattingly et. al. 1994).
The previously reported blockade of the induction and expression of
behavioral sensitization to amphetamine (Feldspausch et. al. 1998) by PNU101387G, and the results from our present study demonstrating a blockade of the
initiation and expression of behavioral sensitization to cocaine, suggests that
behavioral sensitization to cocaine and amphetamine may occur through a common
mechanism involving at least the D4 receptor. This seems likely because although
the mechanism of action of amphetamine and cocaine are different, the final outcome
of both their effects are an increase in synaptic dopamine concentration. The present
findings therefore strongly indicate a role for the D2-like receptors in cocaine
sensitization. In particular, these results demonstrate that dopamine D4 receptors
play a critical role in the induction and expression of behavioral sensitization to
cocaine and amphetamine.
PCP Sensitization
A significant increase in locomotor activity after five days of pretreatment
followed by a challenge dose of PCP after a ten day withdrawal period demonstrates
sensitization . This sensitization was manifested in all three parameters studied,
namely, horizontal activity, vertical activity, and the total distance traveled. An
increase in both the horizontal and vertical activity counts can be explained through
the manual observations. The locomotor sensitization to PCP was evident by the rats
alternating between periods of fast patterned i.e. repetitive exploration with
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hyperactivity and stereotypy (repetitive sniffing/rearing in one location to exclusion
of other activities).

The lack of an effect of PNU-101387G on rats that were

pretreated with the combination of the D4 antagonist and PCP suggests that D4
receptors may not play a role in the development of sensitization to PCP. Similar to
the effects of PNU-101387G on the development of sensitization to PCP, the D4
antagonist failed to also block the expression of sensitization i.e. the locomotor
activity of the P/P+U rats was not significantly different compared to the PIP group.
Therefore, in contrast to the effects of clozapine on PCP-induced sensitization
(Maurel-Remy 1995, Johnson 1998), which could be due to serotonin receptor
blockade by clozapine or some other mechanism, our studies suggest that the D4
dopamine receptor may not play a role in PCP-induced sensitization.
Taken together, these data suggest that differential mechanisms participate in
amphetamine, cocaine vs. PCP sensitization.

Results from asymmetric cross

sensitization studies are consistent with these data. Greenberg and Segal (1985) have
demonstrated that a challenge injection of PCP in amphetamine pre-treated animals
resulted in behavioral sensitization, but pretreatment with PCP decreased the
behavioral response to an amphetamine challenge. Although repeated intermittent
administration of amphetamine and PCP results in behavioral sensitization, there are
also significant pharmacological differences between these two drugs. Amphetamine
and cocaine target monoamine transporters whereas PCP acts as a non-competitive
antagonist of the NMDA type of glutamate receptor and also shows low affinity for
the DA transporter (Javitt and Jukin 1991; Jones et al. 1987).

Also, the

noncompetitive NMDA receptor antagonist, MK-801, blocks sensitization to
amphetamine and cocaine (Karler et al. 1989) but not PCP (Xu and Domino 1994).
Hence distinct pharmacological specificity may be observed for blockade of
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behavioral sensitization to amphetamine, cocaine or PCP.
These studies did not elucidate molecular mechanisms underlying PNU101387G effects on psychostimulant sensitization.

D4 receptors are expressed

predominantly on cortical GABAergic intemeurons and pyramidal neurons
suggesting that D4 receptors are strategically situated to modulate cortical
glutaminergic output. In preliminary studies in this laboratory, it was observed that
+

D4 blockade reduces impulse-dependent (K -induced) glutamate release in the PFC.
+

On the other hand, amp challenges in amp-pretreated rats augments K -induced
glutamate release in the PFC. Taken together, these data suggest that PNU-101387G
induced blockade of amp-sensitization may involve a reduction in glutamate release.
If so, one would argue that sensitization to the glutamate receptor blocker, PCP,
would not be affected by D4 blockade since glutaminergic tone through NMDA
receptors is already reduced by PCP.

Thus the specificity of PNU-101387G in

blocking Amp- and cocaine-induced sensitization but not PCP sensitization is
consistent with the idea that PNU-101387G renders its effects by reducing glutamate
output in the PFC.

CHAPTER VI
CONCLUSIONS
Results from the genomic and behavioral studies clearly demonstrate a role
for D4 dopamine receptors in the modulation of induction and expression of
behavioral sensitization to amphetamine and cocaine but not sensitization to PCP.
The participation of the individual members of the D2-like receptors, especially the
D4 receptor in behavioral sensitization, is now more evident.

These results are

therefore highly significant in advancing our understanding of the mechanisms
underlying sensitization to psychostimulants.
Specifically, the following conclusions can be drawn:
1. The D4 antagonist, PNU-1013870, may not be significantly involved in
modulating amphetamine-induced NGFI-A mRNA expression, suggesting a
predominant role for the Dl-like or other receptors.
2.

The withdrawal phase may be a critical component of the treatment

paradigm since repeated, intermittent administration of amphetamine for five days
without a withdrawal phase did not result in sensitization.
3. The lack of a significant attenuation in c-fos mRNA expression in animals
that failed to demonstrate the development of behavioral sensitization indicates that
behavioral changes observed in response to psychostimulant administration may be a
initiated by the immediate genomic responses.
4.

The D4 antagonist can modulate the behavioral effects of cocaine by

blocking both the development and expression of sensitization and therefore plays a
critical role in cocaine sensitization.
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5.

The lack of any modulation of PCP-induced behavioral sensitization

suggests that PCP-induced sensitization does not involve the D4 receptor but may be
mediated through the Dl -like receptors or through some other non-dopaminergic
mechanism.
Future studies focusing on the role of the D4 antagonist in modulating the
expression of other amphetamine-induced transcription factors including the cAMP
response element binding protein (CREB) would further our understanding of the
genomic changes accompanying the long-term alterations leading to behavioral
sensitization.

In addition, the genomic alterations underlying the modulation of

cocaine-induced behavioral sensitization needs to be examined to further elucidate
the mechanisms underlying the induction and expression of behavioral sensitization
to cocaine and the role of the D4 receptors in this process.

APPENDIX A
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